Effect of Postoperative Coffee Consumption on Postoperative Ileus after Abdominal Surgery: An Updated Systematic Review and Meta-Analysis

Jun Watanabe 1,2,*, Atsushi Miki 1, Masaru Koizumi 1, Kazuhiko Kotani 2, and Naohiro Sata 1

1 Department of Surgery, Division of Gastroenterological, General and Transplant Surgery, Jichi Medical University, Shimotsuke-City 329-0498, Japan; amiki@jichi.ac.jp (A.M.); mkoizumi@jichi.ac.jp (M.K.); sata2018@jichi.ac.jp (N.S.)

2 Division of Community and Family Medicine, Jichi Medical University, Shimotsuke-City 329-0498, Japan; kazukotani@jichi.ac.jp

* Correspondence: m06105jw@jichi.ac.jp; Tel.: +81-285-58-7371; Fax: +81-285-44-3234

Abstract: Background: Previous systematic reviews have not clarified the effect of postoperative coffee consumption on the incidence of postoperative ileus (POI) and the length of hospital stay (LOS). We aimed to assess its effect on these postoperative outcomes. Methods: Studies evaluating postoperative coffee consumption were searched using electronic databases until September 2021 to perform random-effect meta-analysis. The quality of evidence was assessed using the Cochrane risk-of-bias tool. Caffeinated and decaffeinated coffee were also compared. Results: Thirteen trials (1246 patients) and nine ongoing trials were included. Of the 13 trials, 6 were on colorectal surgery, 5 on caesarean section, and 2 on gynecological surgery. Coffee reduced the time to first defecation (mean difference (MD) = −10.1 min; 95% confidence interval (CI) = −14.5 to −5.6), POI (risk ratio 0.42; 95% CI = 0.26 to 0.69); and LOS (MD = −1.5; 95% CI = −2.7 to −0.3). This trend was similar in colorectal and gynecological surgeries. Coffee had no adverse effects. There was no difference in POI or LOS between caffeinated and decaffeinated coffee (p > 0.05). The certainty of evidence was low to moderate. Conclusion: This review showed that postoperative coffee consumption, regardless of caffeine content, likely reduces POI and LOS after colorectal and gynecological surgery.

Keywords: abdominal surgery; caffeine; coffee; ileus; length of stay; meta-analysis; systematic review

1. Introduction

Postoperative ileus (POI), defined as the transient cessation of coordinated bowel motility, is a common cause of delayed return to normal bowel function after abdominal surgery (e.g., colorectal and gynecologic surgery), occurring in 10–15% of cases [1,2]. Delayed defecation associated with POI causes vomiting, bloating, and intolerance to food, and POI often leads to invasive interventions, such as nasogastric tube insertion [3]. POI increases postoperative length of hospital stay (LOS) and treatment-related costs [4,5]. POI and LOS are important postoperative outcomes because prolonged LOS and increased risk of morbidity due to POI have been shown to reduce patients’ quality of life and increase hospital expenditures [4–6].

Coffee is the most widely consumed pharmacological substance worldwide [7]. Caffeine exerts anti-inflammatory effects on the gastrointestinal and cardiovascular systems, mediated by its antagonistic effects on A2A receptors on immune cells, such as T and B cells and macrophages [8,9]. Since the implementation of enhanced recovery protocols (ERPs), multimodal strategies have been used to improve the postoperative return of gastrointestinal function [10,11]. Recommendations regarding the use of postoperative coffee vary in various international ERPs [10,11]. Previous systematic reviews did not demonstrate that LOS and POI were statistically significantly reduced, because of the small
number of trials [12–15]. In addition, it is unclear whether coffee or decaffeinated coffee is effective in treating POI [12].

Coffee, a popular and easily available beverage worldwide, could also be clinically significant if shown to prevent POI incidence in addition to shortening LOS. In terms of ERPs, colorectal and gynecological surgeries are treated similarly because of the manipulation of the bowel [10,11]. Therefore, the present updated systematic review and meta-analysis aimed to assess the effect of postoperative coffee consumption on POI after abdominal surgery, including colorectal surgery, cesarean section, and gynecological surgery.

2. Material and Methods

2.1. Protocol

We followed the Preferred Reporting Items for Systematic Review and Meta-Analysis 2020 (PRISMA 2020) (Appendix A) [16]. This protocol was registered on protocols.io (https://doi.org/10.17504/protocols.io.bymmpu46).

2.2. Inclusion Criteria

Randomized controlled trials (RCTs) that assessed the effect of postoperative coffee consumption after abdominal surgery were included. No language, country, observation period, or publication year restrictions were applied. Review articles, case series, and case reports were excluded. The intervention of interest was postoperative 100–150 mL coffee consumption, three times per day, for 10–20 min. The control group consumed water, tea, or a placebo. The primary outcomes were time to first defecation (hours), LOS (days), and POI. The secondary outcomes were the time to first flatus (hours), the time to first bowel movement (hours), the time to tolerance of solid food (hours), and adverse events.

2.3. Search Method

The following electronic databases and trial registries were searched: MEDLINE (PubMed), Cochrane Central Register of Controlled Trials (Cochrane Library), EMBASE (Dialog) (Appendix B), the World Health Organization International Clinical Trials Platform Search Portal (ICTRP), and ClinicalTrials.gov (Appendix C). The reference lists were checked for studies, including international guidelines [10,11], as well as reference lists of eligible studies and articles citing eligible studies. The authors of the original studies were asked for unpublished or additional data if necessary.

2.4. Data Collection and Analysis

Two independent reviewers (J.W. and A.M.) performed screening, data extraction, and assessment of the risk of bias using the Risk of Bias 2 tool [17] and assessed the quality of evidence based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach [18]. Disagreements between the two reviewers were discussed, and if necessary, a third reviewer (K.K.) was consulted.

The relative risk ratios (RRs) and the 95% confidence intervals (CIs) were calculated for the binary variables, POI, and adverse events. The mean differences (MDs) and 95% CIs were calculated for the continuous variables, LOS (days), the time to first defecation (hours), the time to first flatus (hours), the time to first bowel movement (hours), and time to tolerance of solid food (hours). Intention-to-treat analysis was performed for dichotomous data as far as possible. For continuous data, missing data were not imputed based on the recommendations of the Cochrane handbook [19]. In cases where missing data were not known after contacting the original authors, the standard deviation was calculated using the method provided in the Cochrane handbook [19] or a previously validated method [20]. A random-effects meta-analysis was performed using Review Manager software (RevMan 5.4.2).

2.5. Assessment of Heterogeneity and Reporting Bias

Statistical heterogeneity was evaluated by visual inspection of the forest plots and calculating the $I^2$ statistic ($I^2 = 0–40\%$, might not be important; 30–60\%, moderate hetero-
geneity; 50–90%, substantial heterogeneity; and 75–100%, considerable heterogeneity) [19]. When there was substantial heterogeneity ($I^2 > 50\%$), we assessed the reason for the heterogeneity. Cochrane’s chi-squared test (Q-test) was performed on the $I^2$ statistic, and a $p$-value less than 0.10 was defined as statistically significant. We searched the clinical trial registry system (ClinicalTrials.gov and ICTRP) to assess any reporting bias. Potential publication bias was evaluated through visual inspection of the funnel plots.

2.6. Additional Analysis

The following subgroup analyses were performed: surgery types (colorectal resection, cesarean section, or gynecological resection) and coffee types (caffeinated or decaffeinated coffee). The following sensitivity analysis was performed: exclusion of studies using imputed statistics.

3. Results

Figure 1 shows the study search process. After the removal of duplicates, 1005 records were screened, of which 31 underwent full-text review and 1 article was added after reviewing reference lists. Finally, 27 studies were included in the qualitative synthesis. The 27 studies comprised 9 ongoing trials (NCT 02510911, NCT02639728, NCT03143621, NCT03191877, NCT03712891, NCT04205058, NCT04547868, IRCT20200116046153N1, and CTRI/2021/04/033141), 5 protocols without results (NCT00130026, NCT01130675, NCT02250924, NCT03660267, and NCT03815877), and 13 clinical trials (1246 patients) [21–33].

Table 1 shows the characteristics of the included clinical trials. Of the 13 trials [21–33], 6 were on colorectal surgery, 5 on cesarean section, and 2 on gynecological surgery. The intervention was caffeinated coffee in 10 trials and decaffeinated coffee in 3 trials.
Table 1. The characteristics of the included studies.

| Authors [Ref. No.] | Year | Country | No. | Age, Year | Male, % | Surgical | Coffee | Volume, mL | Frequency | Control |
|---------------------|------|---------|-----|-----------|---------|----------|--------|------------|-----------|---------|
| Müller [21]         | 2012 | Germany | 79  | 61        | 56      | CRS      | Caffeine | 100        | TDS       | Water   |
| Dulskas [22]        | 2015 | Lithuania | 90  | 65        | 53      | CRS      | Caffeine, Decaf | 100        | TDS       | Water   |
| Piric [23]          | 2015 | Bosnia and Herzegovina | 58  | 63        | 59      | CRS      | Caffeine | 100        | TDS       | Tea     |
| Goymen [24]         | 2016 | Turkey   | 75  | 50        | 0       | CS       | Decaf   | 100        | TDS       | Water, no intervention |
| Mohamed [26]        | 2018 | Egypt    | 210 | 55        | 0       | CS       | NR      | NR         | NR        | No intervention |
| Rabiepoor [27]      | 2018 | Iran     | 100 | 28        | 0       | CS       | 100     | 100        | TDS       | Water   |
| Hasler-Gehrer [28]  | 2019 | Switzerland | 115 | 66        | 51      | CRS      | Caffeine | 150        | TDS       | Tea     |
| Hayashi [29]        | 2019 | Japan    | 46  | 77        | 26      | CRS      | Caffeine | 100        | TDS       | Water   |
| Bozkurt Koseoglu [30] | 2020 | Turkey   | 113 | 29        | 0       | CS       | Caffeine | 100        | TDS       | No intervention |
| Kanza Göl [32]      | 2021 | Turkey   | 80  | 28        | 0       | CS       | Decaf   | NR         | TDS       | No intervention |
| Parnasa [33]        | 2021 | Israel   | 70  | 56        | 50      | CRS      | Caffeine | 50 *       | TDS       | Placebo |

CRS, colorectal surgery; CS, caesarean section; GS, gynecological surgery; No., number; NR, not reported; TDS, three times per day.

* 100 mg of caffeine citrate.

The risk of bias is shown in Table 2 and Appendices D and E. In terms of the overall risk of bias for the time to first defecation, there were concerns about the risk of bias for most studies (11/13), with two of these assessed as having a high risk of bias [25,26].

Table 2. Risk of bias for the eligibility studies for the time to first defecation.

| Authors [Ref. No.] | Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias |
|---------------------|--------------------------------------------|--------------------------------------------------|-----------------------------------|----------------------------------------|------------------------------------------|----------------------|
| Müller [21]         | Low                                        | Some concerns                                    | Some concerns                     | Some concerns                          | Some concerns                            | Some concerns        |
| Dulskas [22]        | Some concerns                             | Some concerns                                    | Some concerns                     | Some concerns                          | Some concerns                            | Some concerns        |
| Piric [23]          | Some concerns                             | Some concerns                                    | Some concerns                     | Some concerns                          | Some concerns                            | Some concerns        |
| Goymen [24]         | Low                                        | Low                                              | Low                               | Low                                    | High                                     | High                 |
| Mohamed [26]        | Some concerns                             | High                                             | High                              | High                                    | Some concerns                            | Some concerns        |
| Rabiepoor [27]      | Some concerns                             | Low                                              | Low                               | Some concerns                          | Some concerns                            | Low                  |
| Hasler-Gehrer [28]  | Low                                        | Some concerns                                    | Some concerns                     | Some concerns                          | Low                                      | Some concerns        |
| Hayashi [29]        | Low                                        | Low                                              | Low                               | Low                                    | Some concerns                            | Low                  |
| Bozkurt Koseoglu [30] | Low                                       | Some concerns                                    | Some concerns                     | Some concerns                          | Some concerns                            | Some concerns        |
| Kanza Göl [32]      | Low                                        | Low                                              | Low                               | Some concerns                          | Some concerns                            | Low                  |
| Parnasa [33]        | Low                                        | Some concerns                                    | Some concerns                     | Some concerns                          | Some concerns                            | Some concerns        |

Table 3 summarizes the findings of the GRADE approach. The certainty of the evidence was low to moderate due to the high risk of bias and inconsistency.

Table 3. Summary of findings.

Effect of Postoperative Coffee Consumption after Abdominal Surgery

| Outcomes                | Anticipated Absolute Effects * (95% CI) | Relative Effect (95% CI) | Patient Number (Studies) | Certainty of the Evidence (GRADE) | Comments                                      |
|-------------------------|----------------------------------------|--------------------------|--------------------------|-----------------------------------|-----------------------------------------------|
| Time to first defecation | The median time was 42 h. MD − 10 h (−14 to −5.6) | -                         | 1209 (13 RCTs)           | Moderate *                         | Coffee reduced the time to first defecation.   |
| Length of hospital stay | The median stay was 6 days. MD − 1.5 days (−2.7 to −0.3) | -                         | 905 (9 RCTs)             | Low ab                            | Coffee reduced the length of hospital stay.    |
| Postoperative ileus     | 165 per 1000. 69 per 1000 (43 to 114) | RR 0.42 (0.26 to 0.69)   | 913 (8 RCTs)            | Low ab                            | Coffee reduced postoperative ileus.            |
### Table 3. Cont.

Effect of Postoperative Coffee Consumption after Abdominal Surgery

| Outcomes                        | Anticipated Absolute Effects * (95% CI) | Relative Effect (95% CI) | Patient Number (Studies) | Certainty of the Evidence (GRADE) | Comments                                      |
|---------------------------------|----------------------------------------|--------------------------|--------------------------|-----------------------------------|-----------------------------------------------|
|                                 | Risk with control | Risk with coffee         | Risk with control        |                                    |                                               |
| Time to first flatus            | The median time was 30 h.               | MD $-4.3$ h              | (-8.5 to -0.07)          | 1113 (12 RCT)                     | Low \(^{a,b}\) Coffee reduced the time to first flatus. |
| Time to first bowel sound       | The median time was 10 h.               | MD $-4.3$ h              | (-7.1 to -1.5)           | 683 (6 RCTs)                      | Very low \(^{a,b,c}\) Coffee reduced the time to first bowel sound. |
| Time to tolerance of solid food | The median time was 48 h.               | MD $-9.9$ h              | (-14 to -5.9)            | 833 (8 RCTs)                      | Low \(^{a,b}\) Coffee reduced the time to first tolerance of solid food. |

CI, confidence interval; MD, mean difference; RR, risk ratio. * The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). GRADE Working Group grades of evidence:

- **High certainty**: We are very confident that the true effect lies close to that of the estimated effect. Moderate certainty: We are moderately confident in the estimated effect. The true effect is likely to be close to the estimated effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the estimated effect is limited: The true effect may be substantially different from the estimated effect. Very low certainty: We have very little confidence in the estimated effect. The true effect is likely to be substantially different from the estimated effect.

- \(^{a}\) Downgraded because of a high risk of bias.
- \(^{b}\) Downgraded because of inconsistency due to substantial heterogeneity.
- \(^{c}\) Downgraded because of imprecision due to the small sample size.

### 3.1. Primary Outcomes

#### 3.1.1. Time to First Defecation (Hours)

Coffee reduced the time to first defecation after colorectal surgery (MD $-15.37$ h; 95% CI = $-18.0$ to $-12.75$; $I^2$ = 0%) and gynecological surgery (MD $-12.83$ h; 95% CI = $-22.44$ to $-3.23$; $I^2$ = 92%) but not after cesarean section (MD $-4.79$ h, 95% CI = $-10.32$ to 0.74; $I^2$ = 94%) (Figure 2).

![Figure 2. Forest plot of the time to first defecation.](image-url)
3.1.2. LOS (Days)

Coffee reduced LOS after gynecological surgery (MD $-1.08 \text{ d}; 95\% \text{ CI} = -1.63 \text{ to } -0.54; I^2 = 0\%$) but not after colorectal surgery (MD $-1.78 \text{ d}; 95\% \text{ CI} = -4.31 \text{ to } 0.75; I^2 = 99\%$) and cesarean section (MD $-0.30 \text{ d}; 95\% \text{ CI} = -0.70 \text{ to } 0.10; I^2 = 93\%$) (Figure 3).

![Figure 3. Forest plot of the length of hospital stay.](image)

3.1.3. POI

Coffee reduced POI incidence after cesarean section (RR 0.32; 95% CI = 0.14 to 0.72) and gynecological surgery (RR 0.25; 95% CI = 0.13 to 0.48; $I^2 = 0\%$) but not after colorectal surgery (RR 0.81; 95% CI = 0.40 to 1.63; $I^2 = 0\%$) (Figure 4).

![Figure 4. Forest plot of postoperative ileus.](image)
3.2. Secondary Outcomes

3.2.1. Time to First Flatus (Hours)

Coffee reduced the time to first flatus after abdominal surgery (MD $-4.27$ h; 95% CI = $-8.28$ to $-0.26$; $I^2 = 96\%$) (Figure A1). There was no statistically significant difference between colorectal surgery, cesarean section, or gynecological surgery in the subgroup test ($p = 0.36$).

3.2.2. Time to First Bowel Sound (Hours)

Coffee reduced the time to first flatus after gynecological surgery (MD $-8.87$ h; 95% CI = $-14.65$ to $-3.09$; $I^2 = 86\%$) but not after cesarean section (MD $-1.87$ h; 95% CI = $-4.40$ to 0.66; $I^2 = 93\%$) (Figure A2).

3.2.3. Time to Tolerance of Solid Food (Hours)

Coffee reduced the time to tolerance of solid food after colorectal surgery, cesarean section, and gynecological surgery (MD $-10.11$ h; 95% CI = $-14.26$ to $-5.95$; $I^2 = 95\%$) (Figure A3).

3.2.4. Complications/Adverse Events

There have been no reports of adverse events related to postoperative coffee consumption. Coffee did not increase the risk of complications or adverse events after colorectal surgery (RR 0.85; 95% CI = 0.48 to 1.51; $I^2 = 40\%$) and cesarean section (RR 0.80; 95% CI = 0.23 to 2.81). Coffee decreases complications after gynecological surgery (RR 0.27; 95% CI = 0.13 to 0.53) (Figure A4).

3.3. Additional Analyses

In subgroup analyses of caffeinated vs. decaffeinated coffee (Figures A5–A11), there were statistically significant differences between caffeinated and decaffeinated coffee for the time to first defecation ($p = 0.02$) and the time to tolerance of solid food ($p = 0.04$). However, when analyzed by surgery type, there were no statistically significant differences between caffeinated and decaffeinated coffee for the time to first defecation after colorectal surgery ($p = 0.14$) or cesarean section ($p = 0.51$) (Figure A12) or for the time to tolerance of solid food after cesarean section ($p = 0.35$) (Figure A13). The results of the sensitivity analysis, excluding studies using imputed statistics, were consistent with the original results except for the time to first flatus (Figures A14–A16).

Regarding publication bias, the funnel plots were symmetric, suggesting a no-potential-no-publication bias (Figure A17).

4. Discussion

This systematic review and meta-analysis demonstrated that postoperative coffee consumption likely reduces the time to first defecation, LOS, and POI after abdominal surgery. This trend is similar to the trends after colorectal and gynecological surgeries. Additionally, there was no difference in LOS and POI between caffeinated and decaffeinated coffee intake. This updated evidence is beneficial to both patients and surgeons regarding the practical endpoints of LOS and POI.

In previous systematic reviews [12–15], coffee accelerated the postoperative recovery of gastrointestinal function but did not reduce POI and LOS. The present review in 13 RCTs with 1246 patients extends the findings of previous reviews, showing a novel benefit of coffee for POI and LOS, in addition to standard ERPs. Preventing POI and shortening LOS can potentially affect the quality of life of patients and reduce their social costs by approximately 40–50% per patient [4–6]. In addition, preventing POI and shortening LOS has the potential to reduce hospital expenditures by US$750 million per year [4,5]. On average, the incidence of POI was 60% lower in the coffee group (POI: 6.9%) than in the non-coffee control group (16.5%). With postoperative coffee consumption, LOS was reduced by 1.5 days. Given that other consensus data show that ERPs reduce morbidity...
(RR 0.78) and LOS (−3.1 days) and opioid antagonists, which are frequently used to improve the postoperative course, reduce POI (32%) and LOS (−0.3 days) [34,35], the improved POI and LOS following coffee intake appear to be meaningful in the clinical setting.

The mechanism underlying the effect of coffee on POI is not fully understood. The factors may be caffeine and other substances in coffee, mainly phenolic antioxidants of chlorogenic acid [36]. Caffeine acts positively on inflammation, activating ryanodine-sensitive Ca\(^{2+}\) channels by releasing Ca\(^{2+}\) from the sarcoplasmic reticulum and inhibiting cyclic guanosine monophosphate degradation, thereby promoting nitric oxide synthesis in the endothelium and enhancing caffeine-induced endothelium-dependent vasodilation [37–39]. Caffeine promotes postoperative recovery of gastrointestinal function through vasodilation [32,40]. Chlorogenic acid has beneficial effects on inflammation and pain [41]. Chlorogenic acid has an anti-inflammatory effect by potently inhibiting the production of tumor necrosis factor-α and interleukin-6 by peripheral blood mononuclear cells [42,43]. In addition, chlorogenic acid inhibits edema formation leading to pain and improves pain following inflammatory responses [42]. These effects may prevent POI and/or lead to shorter LOS.

There were no differences in the recovery of postoperative gastrointestinal function between caffeinated and decaffeinated coffee. These results suggest that caffeine and non-caffeine substances may have a positive effect on POI. In previous studies, both caffeinated and decaffeinated coffee similarly reduced the risk of various cancers and death from all causes [44,45]. The results of our study were in accordance with those of previous studies. However, caution should be exercised when interpreting the results due to the small number of studies involving decaffeinated coffee.

In the present review, there were no reports of adverse events related to coffee, although the caffeine group had a higher postoperative systolic blood pressure (mean 120 mmHg) than that of the control group (mean 100 mmHg) [32,46]. The amount of coffee used in this study was a common amount, and considering the safety of coffee, which is widely used, it is not a phenomenon that should be of great concern [47]. Whether hypertensive patients need to refrain from coffee consumption after surgery requires further study.

Our study showed that the certainty of the evidence was low to moderate because of the high risk of bias and inconsistency based on the GRADE approach. The overall risk of bias was high because the concealment of the allocation sequence was unclear, and the outcomes of interest, POI and LOS, were not included in the protocol. Further studies are needed to clarify allocation concealment and clarify outcomes, such as POI and LOS, in protocols. Additionally, the definitions of POI and LOS were unclear and may be affected by blinding and socioeconomic confounds. In the present review, many studies reported that POI was the indication for reinsertion of the nasogastric tube. POI and LOS should be clearly defined and recorded by blinded outcome assessors. When interpreting our results, heterogeneity in variables such as age, comorbidities, and surgical invasiveness in each population undergoing the procedure should be considered. In the case of cesarean section, the impact of coffee on LOS after cesarean section may be small because the hospital stay is short to begin with [48,49]. In the case of colorectal surgery, coffee had a relatively weak effect on POI, which may be due to other factors related to POI, such as postoperative exercise and nutrition [35,50].

This review has additional limitations. First, the dose–response relationship between coffee consumption and outcomes was not evaluated. In the studies included in this review, the amount of coffee consumed was 100–150 mL, three times per day over 10–20 min. Second, the characteristics of coffee consumers, such as the relationship between regular and non-regular coffee drinkers, have not been clearly reported. Third, our results may not be generalizable to all populations because the compounds in coffee may vary by region, bean type, roast, and brewing method. Furthermore, none of the studies included data collected from children or low-income countries.
5. Conclusions

The findings of this updated systematic review and meta-analysis indicate that postoperative coffee consumption, with or without caffeine consumption, may reduce POI and LOS after colorectal surgery, cesarean section, and gynecological surgery. The findings suggest that patients and surgeons should preferably use postoperative coffee to reduce POI. More RCTs are needed to verify the effect of postoperative coffee consumption because the evidence for its consumption is limited by variations in surgeries.

Author Contributions: Conceptualization, J.W. and K.K.; methodology, J.W., A.M. and K.K.; software, J.W. and A.M.; validation, J.W., A.M. and K.K.; formal analysis, J.W. and A.M.; investigation, J.W., A.M., M.K., K.K. and N.S.; resources, J.W., data curation, J.W., A.M. and K.K; writing—original draft preparation, J.W.; writing—review and editing, A.M., M.K., K.K. and N.S; visualization, J.W. and A.M.; supervision, A.M., M.K., K.K. and N.S.; project administration, M.K., K.K. and N.S.; funding acquisition, J.W. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by JSPS KAKENHI Grant Number JP21K21121.

Institutional Review Board Statement: As this review did not involve animals, neither ethical review board approval nor patient consent was required.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data relevant to the study are included in the article.

Acknowledgments: We thank Kentaro Hayashi from the University of Tokyo, Paul Karanicolas from the Sunnybrook Health Sciences Centre, and Noam Shussman from the Hadassah Hebrew University Medical Center for providing us with the additional information necessary for this study.

Conflicts of Interest: The authors declare no conflict of interest in association with the present study.

Appendix A

Table A1. PRISMA 2020 Checklist.

| Section and Topic       | Item | Checklist Item                                                                 | Location Where Item Is Reported |
|-------------------------|------|--------------------------------------------------------------------------------|---------------------------------|
| TITLE                   | 1    | Identify the report as a systematic review.                                    | 1                               |
| ABSTRACT                | 2    | See PRISMA 2020 for the Abstract checklist.                                    | 1                               |
| INTRODUCTION            | 3    | Describe the rationale for the review in the context of existing knowledge.    | 1                               |
| METHODS                 | 4    | Provide an explicit statement of the objective(s) or question(s) the review addresses. | 2                               |
| Eligibility criteria    | 5    | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | 2                               |
| Information sources     | 6    | Specify all databases, registers, websites, organizations, reference lists, and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | 2                               |
| Search strategy         | 7    | Present the full search strategies for all databases, registers, and websites, including any filters and limits used. | Appendices B and C               |
| Section and Topic                  | Item | Checklist Item                                                                 | Location Where Item Is Reported |
|-----------------------------------|------|--------------------------------------------------------------------------------|---------------------------------|
| Selection process                 | 8    | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved; whether they worked independently; and if applicable, details of automation tools used in the process. | 2, 3                            |
| Data collection process           | 9    | Specify the methods used to collect data from reports, including how many reviewers collected data from each report; whether they worked independently; any processes for obtaining or confirming data from study investigators; and if applicable, details of automation tools used in the process. | 2, 3                            |
| Data items                        | 10a  | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | 2, 3                            |
|                                   | 10b  | List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | 2, 3                            |
| Study risk-of-bias assessment     | 11   | Specify the methods used to assess the risk of bias in the included studies, including details of the tool(s) used; how many reviewers assessed each study and whether they worked independently; and if applicable, details of automation tools used in the process. | 2, 3                            |
| Effect measures                   | 12   | Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results. | 2, 3                            |
| Synthesis methods                 | 13a  | Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | 2, 3                            |
|                                   | 13b  | Describe any methods required to prepare the data for presentation; synthesis, such as handling of missing summary statistics; or conversions. | 2, 3                            |
|                                   | 13c  | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | 2, 3                            |
|                                   | 13d  | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | 2, 3                            |
|                                   | 13e  | Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression). | 2, 3                            |
|                                   | 13f  | Describe any sensitivity analyses conducted to assess the robustness of the synthesized results. | 2, 3                            |
| Reporting bias assessment         | 14   | Describe any methods used to assess the risk of bias due to missing results in a synthesis (arising from reporting biases). | 3                               |
| Certainty assessment              | 15   | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | 3                               |
Table A1. Cont.

| Section and Topic          | Item | Checklist Item                                                                 | Location Where Item Is Reported |
|---------------------------|------|--------------------------------------------------------------------------------|---------------------------------|
| RESULTS                   |      |                                                                                |                                 |
| Study selection           | 16a  | Describe the results of the search and selection process, from the number of    | 3                               |
|                           |      | records identified in the search to the number of studies included in the review,|                                 |
|                           |      | ideally using a flow diagram.                                                 |                                 |
|                           | 16b  | Cite studies that might appear to meet the inclusion criteria but were excluded  | 3                               |
|                           |      | and explain why they were excluded.                                           |                                 |
| Study characteristics     | 17   | Cite each included study and present its characteristics.                      | 4                               |
| Risk of bias in studies   | 18   | Present assessments of the risk of bias for each included study.                | 4, Table 2, Appendices D and E   |
| Results of individual     | 19   | For all outcomes, present, for each study: (a) summary statistics for each      | 4, Table 1                       |
| studies                   |      | group (where appropriate) and (b) an effect estimate and its precision (e.g.,   |                                 |
|                           |      | confidence/credible interval), ideally using structured tables or plots.        |                                 |
| Results of syntheses      | 20a  | For each synthesis, briefly summarize the characteristics and the risk of bias   | 5, 6, 7, 8                      |
|                           |      | among contributing studies.                                                    |                                 |
|                           | 20b  | Present results of all statistical syntheses conducted. If meta-analysis was     | 5, 6, 7, 8                      |
|                           |      | done, present for each the summary estimate and its precision (e.g., confidence/ |                                 |
|                           |      | credible interval) and measures of statistical heterogeneity. If comparing     |                                 |
|                           |      | groups, describe the direction of the effect.                                  |                                 |
|                           | 20c  | Present results of all investigations of possible causes of heterogeneity among  | 5, 6, 7, 8                      |
|                           |      | study results.                                                                  |                                 |
|                           | 20d  | Present results of all sensitivity analyses conducted to assess the robustness  | 8                               |
|                           |      | of the synthesized results.                                                     |                                 |
| Reporting biases          | 21   | Present assessments of the risk of bias due to missing results (arising from     | 8                               |
|                           |      | reporting biases) for each synthesis assessed.                                 |                                 |
| Certainty of evidence     | 22   | Present assessments of certainty (or confidence) in the body of evidence for     | Table 3                         |
|                           |      | each outcome assessed.                                                         |                                 |
| DISCUSSION                |      |                                                                                |                                 |
| Discussion                | 23a  | Provide a general interpretation of the results in the context of other        | 8                               |
|                           |      | evidence.                                                                      |                                 |
|                           | 23b  | Discuss any limitations of the evidence included in the review.                 | 9                               |
|                           | 23c  | Discuss any limitations of the review processes used.                           | 9                               |
|                           | 23d  | Discuss implications of the results for practice, policy, and future research.  | 9                               |
| OTHER INFORMATION         |      |                                                                                |                                 |
| Registration and protocol | 24a  | Provide registration information for the review, including the register name     | 2                               |
|                           |      | and the registration number, or state that the review was not registered.       |                                 |
|                           | 24b  | Indicate where the review protocol can be accessed or state that a protocol was | 2                               |
|                           |      | not prepared.                                                                  |                                 |
|                           | 24c  | Describe and explain any amendments to information provided at registration or | 2                               |
|                           |      | in the protocol.                                                               |                                 |
| Support                   | 25   | Describe sources of financial or non-financial support for the review and the   | 9                               |
|                           |      | role of the funders or sponsors in the review.                                 |                                 |
| Competing interests       | 26   | Declare any competing interests of review authors.                              | 10                              |
| Availability of data,     | 27   | Report which of the following are publicly available and where they can be      | 24, 25, 26                      |
| code, and other materials |      | found: template data collection forms, data extracted from included studies,    |                                 |
|                           |      | data used for all analyses, analytic code, and any other materials used in the  |                                 |
|                           |      | review.                                                                        |                                 |
Appendix B. Search Strategy for Electronic Databases

MEDLINE (PubMed) search strategy
#1. (“coffee”[Mesh] OR “coffee”[tiab]) OR (“caffeine”[Mesh] OR “caffeine”[tiab])
#2. (“abdomen”[Mesh] OR “abdomen”[tiab]) OR (“surgical procedures, operative”[Mesh] OR “surgical” OR “producer” OR “operation” OR “operative”)
#3. #1 AND #2
#4. (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR drug therapy[sh] OR placebo [tiab] OR randomly[tiab] OR trial[tiab] OR groups[tiab]) NOT (animals [mh] NOT humans [mh])
#5. #3 AND #4

CENTRAL (Cochrane Library) search strategy
((mh coffee) OR coffee:ti,ab OR ((mh caffeine) OR caffeine:ti,ab)) AND ((mh abdomen) OR abdomen:ti,ab OR abdominal:ti,ab OR ((mh “surgical procedures, operative”) OR surgical OR producer OR operation OR operative))

EMBASE (Dialog) search strategy
S1 (EMB.EXACT.EXPLODE(“coffee”) OR (ab(“coffee”) OR ti(“coffee”))) OR EMB.EXACT.EXPLODE(“caffeine”) OR (ab(“caffeine”) OR ti(“caffeine”)))
S2 EMB.EXACT.EXPLODE(“abdomen”) OR (ab(“abdomen”) OR ti(“abdomen”)) OR (ab(“abdominal”) OR ti(“abdominal”)) OR (EMB.EXACT.EXPLODE(“abdominal surgery”)) OR (ab(“surgical”) OR ti(“surgical”)) OR (ab(“producer”) OR ti(“producer”)) OR (ab(“operation”) OR ti(“operation”)) OR (ab(“operative”) OR ti(“operative”))
S3 S1 AND S2
S4 (ab(random*) OR ti(random*)) OR (ab(placebo*) OR ti(placebo*)) OR (ab(double NEAR/1 blind*) OR ti(double NEAR/1 blind*))
S5 S3 AND S4

Appendix C. Search Strategy for Clinical Trial Registries

ICTRP search strategy
(Coffee OR Caffeine) AND (abdomen OR abdominal OR surgical OR producer OR operation OR operative)

ClinicalTrials.gov search strategy
Condition or disease: (abdomen OR abdominal OR surgical OR producer OR operation OR operative)
Intervention: Coffee OR Caffeine

Appendix D

Table A2. Risk of Bias for Eligibility Studies for the Length of Hospital Stay.

| Authors [Ref No.] | Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias |
|-------------------|--------------------------------------------|--------------------------------------------------|----------------------------------|----------------------------------------|-----------------------------------------------|---------------------|
| Müller [20]       | Low                                        | Some concerns                                   | Some concerns                    | Some concerns                          | Some concerns                                 | Some concerns       |
| Dulskaś [21]      | Some concerns                              | Some concerns                                   | Some concerns                    | Some concerns                          | Some concerns                                 | Some concerns       |
| Piric [22]        | Some concerns                              | Some concerns                                   | Some concerns                    | Some concerns                          | Some concerns                                 | Some concerns       |
| Güngördük [24]    | Low                                        | Low                                             | Some concerns                    | Some concerns                          | Some concerns                                 | High                |
| Mohamed [25]      | Some concerns                              | High                                            | High                             | Some concerns                          | Some concerns                                 | High                |
| Rabiepoor [26]    | Some concerns                              | Low                                             | Low                              | Some concerns                          | Some concerns                                 | Some concerns       |
| Hader-Gehrer [27] | Low                                        | Some concerns                                   | High                             | Some concerns                          | High                                          | High                |
| Hayashi [28]      | Low                                        | Low                                             | Some concerns                    | Low                                    | High                                          | High                |
| Güngördük [30]    | Low                                        | Some concerns                                   | Some concerns                    | High                                    | Some concerns                                 | High                |
| Parnasa [32]      | Low                                        | Some concerns                                   | Some concerns                    | Low                                    | Some concerns                                 | Some concerns       |
Appendix E

Table A3. Risk of Bias for the Eligibility Studies for Postoperative Ileus.

| Authors            | Bias Arising from the Randomization Process | Bias Due to Deviations from Intended Interventions | Bias Due to Missing Outcome Data | Bias in the Measurement of the Outcome | Bias in the Selection of the Reported Results | Overall Risk of Bias |
|--------------------|--------------------------------------------|--------------------------------------------------|----------------------------------|---------------------------------------|-----------------------------------------------|----------------------|
| Müllner [20]       | Low                                        | Some concerns                                    | Some concerns                    | Some concerns                         | Some concerns                                | Some concerns        |
| Dulskas [21]       | Some concerns                              | Some concerns                                    | Some concerns                    | Some concerns                         | Some concerns                                | Some concerns        |
| Piric [22]         | Some concerns                              | Some concerns                                    | Some concerns                    | Some concerns                         | Some concerns                                | Some concerns        |
| Güngördük [24]     | Some concerns                              | Low                                              | Low                              | Some concerns                         | High                                          | High                 |
| Mohamed [23]       | Some concerns                              | High                                              | High                              | Some concerns                         | Some concerns                                | High                 |
| Hadži-Gaber [27]   | Low                                        | Some concerns                                    | Some concerns                    | High                                  | High                                          | High                 |
| Bozkurt Koseoglu [29] | Low                                       | Some concerns                                    | Some concerns                    | High                                  | High                                          | High                 |
| Güngördük [30]     | Low                                        | Some concerns                                    | Some concerns                    | High                                  | High                                          | High                 |
| Parnasa [32]       | Low                                        | Some concerns                                    | Some concerns                    | High                                  | High                                          | High                 |

Figure A1. Forest plot of the time to first flatus.
Figure A2. Forest plot of the time to first bowel sound.

Figure A3. Forest plot of the time to toleration of solid food.
Figure A4. Forest plot of complications/adverse events.

Figure A5. Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee).
Figure A6. Forest plot of length of hospital stay by coffee types (caffeinated or decaffeinated coffee).

Figure A7. Forest plot of postoperative ileus by coffee types (caffeinated or decaffeinated coffee).
**Figure A8.** Forest plot of time to first flatus by coffee types (caffeinated or decaffeinated coffee).

**Figure A9.** Forest plot of time to first bowel sound by coffee types (caffeinated or decaffeinated coffee).
Figure A10. Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee).

Figure A11. Forest plot of complications/adverse events by coffee types (caffeinated or decaffeinated coffee).
Figure A12. Forest plot of time to first defecation by coffee types (caffeinated or decaffeinated coffee) in (A) colorectal surgery and (B) cesarean section.

Figure A13. Forest plot of time to toleration of solid food by coffee types (caffeinated or decaffeinated coffee) in cesarean section.
Figure A14. Forest plot of length of hospital stay excluding studies using imputed statistics.

Figure A15. Forest plot of time to first flatus excluding studies using imputed statistics.
| Study or Subgroup | Coffee | Control | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-------------------|--------|---------|----------------------------------|----------------------------------|
|                  | Mean   | SD      | Mean   | SD      | Weight |                  |                    |
| Colorrect surgery | 49.2   | 21.3    | 40     | 55.8    | 30      | 39      | -6.60 [-18.10, 4.90] |
| Parasa 2021      | 93.6   | 18.59   | 109.6  | 19.44   | 28      | 10.3%   | -16.00 [-25.80, -6.20] |
| Subtotal (95% CI)| 70     | 67      | 67     | 18.9%   | -11.80 [-20.96, -2.64] |
| Heterogeneity:   |         |         |         |         |         |         |                  |
| Tau² = 14.46;    |         |         |         |         |         |         |                  |
| Chi² = 1.49; df = |         |         |         |         |         |         |                  |
| 1 (P = 0.22); I² = 33% |
| Test for overall effect Z = 2.53 (P = 0.01) |         |         |         |         |         |         |                  |

| Cesarean section | Coffee | Control | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|------------------|--------|---------|----------------------------------|----------------------------------|
|                  | Mean   | SD      | Mean   | SD      | Weight |                  |                    |
| Rabiepoor 2018   | 13.1   | 1.9     | 50     | 12.84   | 1.76   | 50      | 22.2%   | 0.26 [0.46, 0.98]  |
| Mohamed 2018     | 16.6   | 0.1     | 97     | 29.5    | 10.6   | 99      | 20.6%   | -10.90 [-13.55, -8.25] |
| Bozkurt Koseoglu 2020 | 8.78   | 2.33    | 51     | 12.88   | 2.6    | 52      | 22.0%   | -4.10 [-5.05, -3.15] |
| Subtotal (95% CI)| 198    | 200     | 64.7%  |         | -4.72  [-9.30, -0.13] |
| Heterogeneity:   |         |         |         |         |         |         |                  |
| Tau² = 15.70;    |         |         |         |         |         |         |                  |
| Chi² = 99.40; df = 2 (P < 0.00001); I² = 98% |
| Test for overall effect Z = 2.02 (P = 0.04) |         |         |         |         |         |         |                  |

| Gynecological surgery | Coffee | Control | Mean Difference IV, Random, 95% CI | Mean Difference IV, Random, 95% CI |
|-----------------------|--------|---------|----------------------------------|----------------------------------|
|                       | Mean   | SD      | Mean   | SD      | Weight |                  |                    |
| Gungoruk 2017         | 04     | 28.8    | 58     | 115.2   | 38.4   | 56      | 7.7%    | -31.20 [-43.69, -18.71] |
| Gungoruk 2020         | 48     | 18      | 49     | 72      | 36     | 47      | 8.6%    | -24.00 [-35.46, -12.54] |
| Subtotal (95% CI)     | 107    | 103     | 16.3%  |         | -27.29 [-35.73, -18.84] |
| Heterogeneity:        |         |         |         |         |         |         |                  |
| Tau² = 0.00; Chi² = 0.69; df = 1 (P = 0.41); I² = 0% |
| Test for overall effect Z = 6.33 (P < 0.00001) |         |         |         |         |         |         |                  |
| Total (95% CI)        | 375    | 370     | 100.0% |         | -9.78  [-14.08, -5.49] |
| Heterogeneity:        |         |         |         |         |         |         |                  |
| Tau² = 21.56; Chi² = 143.68; df = 6 (P < 0.00001); I² = 98% |
| Test for overall effect Z = 4.48 (P < 0.00001) |         |         |         |         |         |         |                  |
| Test for subgroup differences: Chi² = 21.35; df = 2 (P = 0.0001); I² = 90.6% |

**Figure A16.** Forest plot of time to toleration of solid food excluding studies using imputed statistics.

**Figure A17.** The funnel plot.
References

1. Wolff, B.G.; Viscusi, E.R.; Delaney, C.P.; Du, W.; Techner, L. Patterns of gastrointestinal recovery after bowel resection and total abdominal hysterectomy: Pooled results from the placebo arms of alvimopan phase III North American clinical trials. J. Am. Coll. Surg. 2007, 205, 43–51. [CrossRef] [PubMed]

2. Scarborough, J.E.; Schumacher, J.; Kent, K.C.; Heise, C.P.; Greenberg, C.C. Associations of specific postoperative complications with outcomes after elective colon resection: A procedure-targeted approach toward surgical quality improvement. JAMA Surg. 2017, 152, e164681. [CrossRef]

3. Gero, D.; Gié, O.; Hübner, M.; Demartines, N.; Hahnloser, D. Postoperative ileus: In search of an international consensus on definition, diagnosis, and treatment. Langenbecks Arch. Surg. 2017, 402, 149–158. [CrossRef] [PubMed]

4. Iyer, S.; Saunders, W.B.; Stemkowski, S. Economic burden of postoperative ileus associated with colectomy in the United States. J. Manag. Care Pharm. 2009, 15, 485–494. [CrossRef] [PubMed]

5. Asgeirsson, T.; El-Badawi, K.I.; Mahmood, A.; Barletta, J.; Luchtefeld, M.; Senagore, A.J. Postoperative ileus: It costs more than you expect. J. Am. Coll. Surg. 2010, 210, 228–231. [CrossRef] [PubMed]

6. Peters, E.G.; Pattamatta, M.; Smeets, B.J.J.; Brinkman, D.J.; Evers, S.M.A.A.; de Jonge, W.J.; Hiligsmann, M.; Luyer, M.D.P. The clinical and economical impact of postoperative ileus in patients undergoing colorectal surgery. Neurogastroenterol. Motil. 2020, 32, e13862. [CrossRef]

7. Abalo, R. Coffee and caffeine consumption for human health. Nutrients 2021, 13, 2918. [CrossRef] [PubMed]

8. Mattioli, A.V. Effects of caffeine and coffee consumption on cardiovascular disease and risk factors. Future Cardiol. 2007, 3, 203–212. [CrossRef] [PubMed]

9. Joos, G.; Jákim, J.; Kiss, B.; Szamosi, R.; Papp, T.; Felszeghy, S.; Ságty, T.; Nagy, G.; Szondy, Z. Involvement of adenosine A3 receptors in the chemotactic migration of macrophages towards apoptotic cells. Immunol. Lett. 2017, 183, 62–72. [CrossRef] [PubMed]

10. Gustafsson, U.O.; Scott, M.J.; Hubner, M.; Nygren, J.; Demartines, N.; Francis, N.; Rockall, T.A.; Young-Fadok, T.M.; Hill, A.G.; Soop, M.; et al. Guidelines for perioperative care in elective colorectal surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World J. Surg. 2019, 43, 659–695. [CrossRef]

11. Nelson, G.; Bakkum-Gamez, J.; Kalogera, E.; Glaser, G.; Altman, A.; Meyer, L.A.; Taylor, J.S.; Iniesta, M.; Lasala, J.; Mena, G.; et al. Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update. Int. J. Gynecol. Cancer 2019, 29, 651–668. [CrossRef] [PubMed]

12. Eamudomkarn, N.; Kietpeerakool, C.; Kaewrudee, S.; Jampathong, N.; Ngamjarus, C.; Lumbiganon, P. Effect of postoperative coffee consumption on gastrointestinal function after abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 2018, 8, 17349. [CrossRef] [PubMed]

13. Gkegkes, I.D.; Minis, E.E.; Iavazzo, C. Effect of caffeine intake on postoperative ileus: A systematic review and meta-analysis. Dig. Surg. 2020, 37, 22–31. [CrossRef] [PubMed]

14. Cornwall, H.L.; Edwards, B.A.; Curran, J.F.; Boyce, S. Coffee to go? The effect of coffee on resolution of ileus following abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. Dis. Colon Rectum. 2012, 55, 999–1007. [CrossRef] [PubMed]

15. Shamseer, L.; Moher, D.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A.; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation. BMJ 2015, 350, g7647. [CrossRef]

16. Nijman, R.; Goymen, A.; Simsek, Y.; Ozkaplan, S.E.; Ozdurak, H.I.; Akpak, Y.K.; Semiz, A.; Oral, S. Effect of gum chewing and coffee consumption on intestinal motility in caesarean sections. J. Clin. Anal. Med. 2017, 8, 411e5. [CrossRef] [PubMed]

17. Büchler, M.W. Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. Langenbecks Arch. Surg. 2015, 400, 57–62. [CrossRef] [PubMed]

18. Eamudomkarn, N.; Kietpeerakool, C.; Kaewrudee, S.; Jampathong, N.; Ngamjarus, C.; Lumbiganon, P. Effect of postoperative coffee consumption on gastrointestinal function after abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 2018, 8, 17349. [CrossRef] [PubMed]

19. Higgins, J.P.T.; Thomas, J. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2. 2021. Available online: https://training.cochrane.org/handbook/current (accessed on 29 September 2021).

20. Eamudomkarn, N.; Kietpeerakool, C.; Kaewrudee, S.; Jampathong, N.; Ngamjarus, C.; Lumbiganon, P. Effect of postoperative coffee consumption on gastrointestinal function after abdominal surgery: A systematic review and meta-analysis of randomized controlled trials. Sci. Rep. 2018, 8, 17349. [CrossRef] [PubMed]

21. Goymen, A.; Simsek, Y.; Ozkaplan, S.E.; Ozdurak, H.I.; Akpak, Y.K.; Semiz, A.; Oral, S. Effect of gum chewing and coffee consumption on intestinal motility in caesarean sections. J. Clin. Anal. Med. 2017, 8, 411e5. [CrossRef] [PubMed]
25. Güngördük, K.; Özdemir, İ.A.; Güngördük, Ö.; Gülseren, V.; Gokçu, M.; Sanci, M. Effects of coffee consumption on gut recovery after surgery of gynecological cancer patients: A randomized controlled trial. *Am. J. Obstet. Gynecol.* 2017, 216, 145.e1–145.e7. [CrossRef] [PubMed]

26. Mohamed, S. Immediate Postoperative Coffee Consumption Stimulates Early Gut Recovery after Cesarean Section. 2018. Available online: https://www.semanticscholar.org/paper/Immediate-Postoperative-Coffee-Consumption-Early-Sherbeny/86790eb679799bea8afaae3fe5010167ae166d0?p2df (accessed on 1 October 2021).

27. Rabieepoor, S.; Yas, A.; Navaei, J.; Khalkhal, H.R. Does coffee affect the bowel function after caesarean section? *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2018, 220, 96–99. [CrossRef]

28. Hasler-Gehrer, S.; Linecker, M.; Keerl, A.; Slieker, J.; Descloux, A.; Rosenberg, R.; Seifert, B.; Nocito, A. Does coffee intake reduce postoperative ileus after laparoscopic elective colorectal surgery? A prospective, randomized controlled study: The coffee study. *Dis. Colon Rectum* 2019, 62, 997–1004. [CrossRef]

29. Hayashi, K.; Tsunoda, A.; Shiraiishi, A.; Kusunagi, H. Quantification of the effects of coffee on postoperative ileus after laparoscopic ventral rectopexy: A randomized controlled trial. *Eur. Surg.* 2019, 51, 325–332. [CrossRef]

30. Bozkurt Koseoglu, S.; Korkmaz Toker, M.; Gokbel, I.; Celikkol, O.; Gungorduk, K. Can coffee consumption be used to accelerate the recovery of bowel function after caesarean section? Randomized prospective trial. *Ginekol. Pol.* 2020, 91, 85–90. [CrossRef]

31. Gungorduk, K.; Paskal, E.K.; Demirayak, G.; Koseoglu, S.B.; Akbaba, E.; Ozdemir, I.A. Coffee consumption for recovery of intestinal function after laparoscopic gynecological surgery: A randomized controlled trial. *Int. J. Gastrointest. Surg.* 2020, 82, 130–135. [CrossRef] [PubMed]

32. Kanza Gül, D.; ¸ Solt Kırca, A. Effects of acupressure, gum chewing and coffee consumption on the gastrointestinal system after caesarean section under spinal anaesthesia. *Int. J. Obstet. Gynaecol.* 2021, 41, 573–580. [CrossRef]

33. Parnasa, S.Y.; Marom, G.; Bdolah-Abram, T.; Gefen, R.; Luques, L.; Michael, S.; Mizrahi, I.; Abu-Gazala, M.; Rivkind, A.I.; Mintz, Y.; et al. Does caffeine enhance bowel recovery after elective colorectal resection? A prospective double-blinded randomized clinical trial. *Tech. Coloproctol.* 2021, 25, 831–839. [CrossRef] [PubMed]

34. Lohsiriwat, V.; Jitmungngan, R.; Chadbunchachai, W.; Ungprasert, P. Enhanced recovery after surgery in emergency resection for obstructive colorectal cancer: A systematic review and meta-analysis. *Eur. J. Gastrointest. Oncol.* 2020, 12, 1453–1461. [CrossRef] [PubMed]

35. McKechnie, T.; Anpalagan, T.; Ichhpuniani, S.; Lee, Y.; Ramji, K.; Eskicioglu, C. Selective opioid antagonists following bowel resection for prevention of postoperative ileus: A systematic review and meta-analysis. *J. Gastrointest. Surg.* 2021, 25, 1601–1624. [CrossRef] [PubMed]

36. Mattioli, A.V.; Migaldi, M.; Farinetti, A. Coffee in hypertensive women with asymptomatic peripheral arterial disease: A potential nutraceutical effect. *J. Cardiovasc. Med.* 2018, 19, 183–185. [CrossRef] [PubMed]

37. Echeverri, D.; Montes, F.R.; Cabrera, M.; Galán, A.; Prieto, A. Caffeine’s Vascular Mechanisms of Action. *Int. J. Vasc. Med.* 2010, 2010, 834060. [CrossRef] [PubMed]

38. Mattioli, A.V.; Nasi, M.; Farinetti, A.; Gelmini, R. Effects of caffeine on colon: A potential clinical use of coffee in surgical patients. *Dig. Surg.* 2020, 37, 265–266. [CrossRef] [PubMed]

39. Cui, W.Q.; Wang, S.T.; Pan, D.; Chang, B.; Sang, L.X. Caffeine and its main targets of colorectal cancer. *World J. Gastrointest. Oncol.* 2020, 12, 149–172. [CrossRef] [PubMed]

40. Liu, D.; Jing, X.; Cao, S.; Liu, X.; Tan, X.; Jiang, H.; Niu, Z.; Su, M.; Zhang, J.; Zhang, X.; et al. Impact of drinking Chinese green tea on postoperative short outcomes for gastric cancer: A randomized controlled trial. *Eur. J. Clin. Nutr.* 2021, 75, 1568–1577. [CrossRef] [PubMed]

41. Tajik, N.; Tajik, M.; Mack, I.; Enck, P. The potential effects of chlorogenic acid, the main phenolic components in coffee, on health: A comprehensive review of the literature. *Nutrients* 2017, 56, 2215–2244. [CrossRef]

42. Dos Santos, M.D.; Almeida, M.C.; Lopes, N.P.; de Souza, G.E. Evaluation of the anti-inflammatory, analgesic and antipyretic activities of the natural polyphenol chlorogenic acid. *Biol. Pharm. Bull.* 2006, 29, 2236–2240. [CrossRef]

43. Krakauer, T. The polyphenol chlorogenic acid inhibits staphylococcal exotoxin-induced inflammatory cytokines and chemokines. *Immunopharmacol. Immunotoxicol.* 2002, 24, 113–119. [CrossRef] [PubMed]

44. Li, Q.; Liu, Y.; Sun, X.; Yin, Z.; Li, H.; Cheng, C.; Liu, L.; Zhang, R.; Liu, E.; Zhou, Q.; et al. Caffeinated and decaffeinated coffee consumption and risk of all-cause mortality: A dose-response meta-analysis of cohort studies. *J. Hum. Nutr. Diet.* 2019, 32, 279–287. [CrossRef] [PubMed]

45. Kennedy, O.J.; Roderick, P.; Buchanan, R.; Fellowfield, J.A.; Hayes, P.C.; Parkes, J. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: A systematic review and dose-response meta-analysis. *BMJ Open* 2017, 7, e013739. [CrossRef] [PubMed]

46. Casiglia, E.; Bongiovi, S.; Paleari, C.D.; Petucco, S.; Boni, M.; Colangelo, G.; Penzo, M.; Pessina, A.C. Haemodynamic effects of coffee and caffeine in normal volunteers: A placebo-controlled clinical study. *J. Intern. Med.* 1991, 229, 501–504. [CrossRef] [PubMed]

47. Ribeiro, E.M.; Alves, M.; Costa, J.; Ferreira, J.J.; Pinto, F.J.; Caldeira, D. Safety of coffee consumption after myocardial infarction: A systematic review and meta-analysis. *Nutr. Metab. Cardiovasc. Dis.* 2020, 30, 2146–2158. [CrossRef] [PubMed]

48. Kelly, A.J.; Alfirevic, Z.; Ghosh, A. Outpatient versus inpatient induction of labour for improving birth outcomes. *Cochrane Database Syst. Rev.* 2013, 11, CD007372. [CrossRef] [PubMed]
49. Pereira Gomes Morais, E.; Riera, R.; Porfirio, G.J.; Macedo, C.R.; Sarmento Vasconcelos, V.; de Souza Pedrosa, A.; Torloni, M.R. Chewing gum for enhancing early recovery of bowel function after caesarean section. *Cochrane Database Syst. Rev.* 2016, 10, CD011562. [CrossRef]

50. Hamel, J.F.; Sabbagh, C.; Alves, A.; Regimbeau, J.M.; Vignaud, T.; Venara, A. Comparison of treatment to improve gastrointestinal functions after colorectal surgery within enhanced recovery programmes: A systematic review and meta-analysis. *Sci. Rep.* 2021, 11, 7423. [CrossRef]